Compare Abbott Laboratories (ABT) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Workiva Inc — how do they compare? Abbott Laboratories trades at $109.6 (market cap $187.95B), while Workiva Inc trades at $68.99 (market cap $3.66B). The key difference: Abbott Laboratories is far larger — about 51.4× Workiva Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| ABT | WK | |
|---|---|---|
Market Cap | $187.95B | $3.66B |
Sector | Health | Technology |
52-Week High | $136.62 | $93.31 |
52-Week Low | $82.57 | $44.31 |
Enterprise Value | $214.96B | $3.64B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Workiva (WK) trades at $65.14, up 4.98% with strong bullish momentum. The stock shows positive technical signals with recent earnings beats and revenue growth of 19% year-over-year in Q2 2026. Analyst consensus is overwhelmingly bullish with 16 buy ratings and an average price target of $69.00. The company's AI platform expansion and strong subscription growth support continued momentum.
Outlook remains positive with improving profitability and strategic AI investments, though high valuation multiples and RSI levels near 70 suggest potential near-term consolidation. Key risks include execution challenges and competitive pressures in the compliance software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
